Products from BPS Bioscience require a minimum order value above 400€
Encompassing Amino Acids: 29-549
Application: Useful for studying enzyme kinetics, substrate specificity, and screening inhibitors.
Assay Conditions: Assay was performed according to CD73 Inhibitor Screening Assay Kit (BPS Bioscience #72055) with CD73 enzyme titrated at various concentrations.
Background: CD73, or cluster of differentiation 73, is an enzyme which hydrolyzes AMP to adenosine. Increased concentrations of adenosine in the microenvironment has an immunosuppressive effect and promotes tumor cell growth.Adenosine can enhance tumor growth via two mechanisms – 1) binding of adenosine to A2A and A2B receptors expressed on tumor cells directly promotes tumor cell proliferation and 2) binding of adenosine to A2A and A2B receptors on immune cells such as also inhibits the activity of pro-inflammatory, anti-tumor immune cells like CD4+ T Cells, CTLs, dendritic cells, NK cells, while and activating immunosuppressant cells like Tregs, MDSCs and TAMs.Development of inhibitory antibodies and small molecules against CD73 could serve as a new therapeutic strategy in the treatment of cancer. In preclinical models have provided proof of concept for this hypothesis as inhibition of CD73 in mouse models has resulted in anti-tumor effects.
Description: Recombinant mouse CD73 (5'-nucleotidase), encompassing amino acids 29-549. This construct contains a C-terminal Avi-His-tag (6xHis). This recombinant protein was affinity purified.
Format: Aqueous buffer solution
Formulation: 8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
Genbank: NM_011851
Host Cell Line: HEK293
Purity: ≥90%
Storage Stability: At least 6 months at -80° C
Tags: Avi-His-Tag
Uniprot: Q61503
Warnings: Avoid freeze/thaw cycles. Storing diluted protein is not recommended, if necessary, use carrier protein (BSA 0.1 - 0.5%).
Biosafety Level: Not applicable (BSL-1)
References: 1.Deaglio, S. et al., J. Exp. Med. 2007; 204(6): 1257-1265.2.Thompson, L.F., et al., J. Exp. Med. 2004; 200(11): 1395-1405.